BIO-TECHNE Corp

Bio-Techne Corporation (NASDAQ: TECH) develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two primary segments: Protein Sciences, which represents approximately 72 percent of net sales, and Diagnostics and Spatial Biology, which accounts for approximately 28 percent of net sales.

The Protein Sciences segment comprises the Reagent Solutions and Analytical Solutions divisions. Reagent Solutions specializes in high-quality proteins including cytokines, growth factors, antibodies, and small molecules used in life science research and therapeutic development, with key brands including R&D Systems, Tocris Biosciences, and Novus Biologicals. Analytical Solutions offers manual and automated protein analysis instruments and immunoassays for quantifying proteins in biological fluids, including automated western blotting and multiplexed ELISA workflows under the R&D Systems and ProteinSimple brands.

The Diagnostics and Spatial Biology segment includes the Spatial Biology and Bio-Techne Diagnostic divisions. Spatial Biology develops in-situ hybridization assays and instrumentation for spatial genomic analysis under the Advanced Cell Diagnostics brand, enhanced by the fiscal 2024 acquisition of Lunaphore, which provides automated spatial biology solutions. The Bio-Techne Diagnostic division manufactures regulated diagnostic products including calibrators, controls, and assays for clinical settings, along with genetic and oncology kits sold under the Asuragen brand.

Bio-Techne was founded in 1976 as Research and Diagnostic Systems, Inc. and became publicly traded in 1985 through a merger with Techne Corporation. The company maintains global headquarters in Minneapolis, Minnesota, with manufacturing operations across North America, the United Kingdom, Canada, Switzerland, and China. As of June 30, 2026, the company employed approximately 3,000 full-time and part-time employees, with roughly 2,200 in the United States and 800 internationally.

The company introduced over 1,900 new products in fiscal 2026 and maintains a portfolio of hundreds of thousands of diverse products. Bio-Techne's website is located at https://investors.bio-techne.com/. In June 2026, the company entered into a merger agreement with Merck KGaA, Darmstadt, Germany, with an expected closing by late 2026 or early 2027.